Decoy Therapeutics Inc. (DCOY) Form 424B3 — Oct 16, 2026
Decoy Therapeutics filed a 424B3 prospectus registering the resale of up to 2,368,868 shares issuable upon exercise of New Warrants issued to Armistice Capital Master Fund Ltd. in a September 2026 warrant inducement private placement. The company received approximately $3.85 million in gross proceeds when Armistice exercised its existing Series B warrants at a reduced $3.25 price (down from $5.91), and issued new warrants at 200% warrant coverage as consideration.
Key figures
- Cash Position
- 8000000
- Gross Proceeds
- 3850000
- Offering Price
- 3.25
- Shares Offered
- 2368868
- Shares Outstanding
- 2385282
- Last Sale Price
- 1.55
- Restricted Cash
- 2500000
- Warrant Coverage Percent
- 200
- New Warrant Exercise Price
- 3.25
- Prior Warrant Exercise Price
- 5.91
- Shares Outstanding After Offering
- 4754150
- Shares Underlying Exercised Warrants
- 1184434
- Max Potential Cash From New Warrant Exercise
- 7700000
- Selling Stockholder Ownership After Percent
- 29.6
- Selling Stockholder Ownership Prior Percent
- 64.68
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.